GlassScriptPhysician profile
Tracie M Watson
NPI 1275875965
$8,152.65
in general payments reported to CMS, 2019-2025
65 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $218 · 2021: $1,596 · 2022: $1,140 · 2023: $1,523 · 2024: $1,568 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289 · Education: $25.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.77 |
| Education | $25.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $612.10 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $534.31 | 2019-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $474.77 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $409.85 | 2021-2025 | Erleada, Akeega, Balversa |
| Kite Pharma, INC. | $388.22 | 2021-2024 | Yescarta |
| Genzyme Corporation | $336.54 | 2020-2025 | |
| Seagen INC. | $330.10 | 2019-2023 | Padcev |
| Glaxosmithkline, LLC. | $319.13 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $309.42 | 2021-2025 | |
| Daiichi Sankyo INC. | $305.13 | 2021-2025 | Injectafer, Enhertu, Datroway |
| Astellas Pharma US INC | $298.52 | 2019-2024 | Padcev, Xtandi |
| Celgene Corporation | $282.74 | 2021-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $264.55 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $264.42 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $227.97 | 2019-2024 | Ninlaro, Alunbrig, Vonvendi |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.75 | 2021-2025 | Venclexta |
| Amgen INC. | $210.31 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Lilly USA, LLC | $161.39 | 2021-2025 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $143.77 | 2021-2024 | Zoladex |
| Myovant Sciences INC. | $125.66 | 2021-2022 | |
| Incyte Corporation | $116.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.85 | 2022-2025 | |
| Puma Biotechnology, INC. | $93.32 | 2021-2025 | |
| Emd Serono, INC. | $91.48 | 2023-2024 | Tepmetko |
| Ipsen Biopharmaceuticals, INC | $88.34 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $74.30 | 2022-2024 | |
| Genentech USA, INC. | $74.20 | 2021-2025 | Venclexta |
| Alexion Pharmaceuticals, INC. | $73.95 | 2019 | |
| Octapharma USA, INC. | $66.56 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Spectrum Pharmaceuticals INC. | $63.21 | 2023 | Rolvedon |
| Array Biopharma INC | $61.23 | 2024-2025 | Xalkori, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $61.05 | 2021-2024 | Libtayo |
| Sumitomo Pharma America, INC. | $58.60 | 2023 | Orgovyx |
| Sobi, INC | $58.28 | 2024-2025 | |
| Kyowa Kirin, INC. | $55.51 | 2024-2025 | Poteligeo |
| Beigene USA, INC. | $51.46 | 2022-2024 | Brukinsa |
| Taiho Oncology, INC. | $49.79 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $48.16 | 2025 | Monoferric |
| Eisai INC. | $46.62 | 2021-2025 | |
| Blueprint Medicines Corporation | $33.05 | 2025 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $31.37 | 2021 | |
| Immunocore Limited | $31.32 | 2024 | Kimmtrak |
| Gilead Sciences, INC. | $29.37 | 2021-2023 | Trodelvy |
| Foundation Medicine, INC. | $28.80 | 2023 | |
| Adaptive Biotechnologies Corporation | $27.59 | 2023 | Clonoseq |
| Genmab U.S., INC. | $26.80 | 2023 | Epkinly |
| Stemline Therapeutics INC. | $26.20 | 2024 | Orserdu |
| Rigel Pharmaceuticals, INC. | $25.82 | 2023 | Rezlidhia, Tavalisse |
| Invivyd INC | $25.42 | 2025 | Pemgarda |
| Acrotech Biopharma INC. | $25.08 | 2025 | Beleodaq |
| Springworks Therapeutics, INC. | $24.51 | 2025 | Ogsiveo |
| Exelixis INC. | $24.47 | 2024 | Cabometyx |
| Beone Medicines USA, INC. | $22.71 | 2025 | Brukinsa |
| Epizyme, INC. | $22.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.31 | 2022 | |
| Apellis Pharmaceuticals, INC. | $21.90 | 2022 | |
| Deciphera Pharmaceuticals INC. | $21.53 | 2022 | |
| Galvanize Therapeutics, INC | $20.99 | 2023 | Aliya System |
| Amag Pharmaceuticals, INC. | $20.14 | 2021 | |
| Heron Therapeutics, INC. | $19.35 | 2022 | |
| Accord Healthcare, INC. | $19.25 | 2025 | |
| Adc Therapeutics America, INC. | $14.63 | 2024 | |
| Amneal Pharmaceuticals LLC | $13.70 | 2024 | Avastin, Neupogen, Neulasta |
| Morphosys, US INC. | $13.01 | 2022 | |
| Clovis Oncology, INC. | $8.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.